-
For patients with colorectal cancer whose tumors overexpressed COX-2, regular aspirin use was associated with a lower risk of death related to colorectal cancer for about 12 years after initial diagnosis.
-
Tamoxifen and CYP2D6 inhibitors, FDA Actions, and FDA Warnings.
-
A non-iodinated derivative of amiodarone has been approved by the FDA for the treatment of atrial fibrillation and atrial flutter.
-
-
After taking the necessary diagnostic steps, the results are clear: The patient sitting in front of you needs to be treated for bacterial vaginosis (BV). The most common vaginal infection in women of childbearing age, women with BV may present with a white or gray discharge, odor, pain, or burning during urination. Symptoms aren't always present, though. More than 50% of women with BV may be asymptomatic.
-
With the wide array of birth control options available today, are adolescents still relying on coitus interruptus? Results of a 2009 study indicate that clinicians should not consider use of contraceptive withdrawal infrequent among teens.
-
Findings from new research may aid clinicians in identifying women who are likely to gain weight while using depot medroxyprogesterone acetate (DMPA, Depo Provera). Research indicates that DMPA users whose weight increased by 5% within the first six months of use are at risk of continued, excessive weight gain.
-
Women who want a permanent form of birth control now have a new option. The Food and Drug Administration (FDA) has approved the Adiana permanent contraception system, manufactured by Hologic of Bedford, MA.
-
-
If your facility provides comprehensive sexually transmitted disease care for men who have sex with men (MSM), be sure to incorporate new guidance from the Centers for Disease Control and Prevention (CDC) regarding gonorrhea and chlamydia testing.